Tony Fiorino
Director/Board Member en IMMUNE PHARMACEUTICALS, INC. .
Perfil
Anthony S.
Fiorino is the founder of EnzymeRx LLC, which was founded in 2008.
He held the title of President & Chief Executive Officer in 2012.
He is currently working as a Director at Immune Pharmaceuticals, Inc. since 2017.
In his former positions, he served as the Chief Executive Officer at Brainstorm Cell Therapeutics, Inc. from 2014 to 2015, President & Chief Executive Officer at Triumvira Immunologics, Inc. from 2015 to 2017, and as an Independent Director at Navidea Biopharmaceuticals, Inc. from 2016 to 2017.
He also worked as a Managing Director at Greywall Asset Management LP from 2013 to 2014.
Additionally, he held positions at Pequot Capital Management, Inc., Sands Point Partners LP, JPMorgan Services (Malaysia) Sdn.
Bhd., electroCore, Inc., and Alchimia Partners LLC.
Dr. Fiorino completed his undergraduate degree at Massachusetts Institute of Technology in 1989 and received his doctorate degree from Albert Einstein College of Medicine, Inc. in 1996 and 1995.
Cargos activos de Tony Fiorino
| Empresas | Cargo | Inicio |
|---|---|---|
| IMMUNE PHARMACEUTICALS, INC. | Director/Board Member | 06/03/2019 |
Antiguos cargos conocidos de Tony Fiorino.
| Empresas | Cargo | Fin |
|---|---|---|
| NAVIDEA BIOPHARMACEUTICALS, INC. | Director/Board Member | 09/10/2017 |
Triumvira Immunologics, Inc.
 Triumvira Immunologics, Inc. Pharmaceuticals: MajorHealth Technology Triumvira Immunologics, Inc. develops and manufactures pharmaceutical products. The company was founded by Jonathan Bramson in 2015 and is headquartered in Hamilton, Canada. | Chief Executive Officer | 01/01/2017 |
| BRAINSTORM CELL THERAPEUTICS INC. | Chief Executive Officer | 01/11/2015 |
Greywall Asset Management LP
 Greywall Asset Management LP Investment ManagersFinance Greywall Asset Management LP is a hedge fund manager located in New York City. | Corporate Officer/Principal | 01/05/2014 |
EnzymeRx LLC
 EnzymeRx LLC BiotechnologyHealth Technology EnzymeRx LLC develops pegylated uricase for the treatment of resistant and refractory related indications. The company was founded by Anthony S Fiorino in 2008 and is headquartered in Paramus, NJ. | Chief Executive Officer | 01/12/2012 |
Formación de Tony Fiorino.
| Massachusetts Institute of Technology | Undergraduate Degree |
| Albert Einstein College of Medicine, Inc. | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| NAVIDEA BIOPHARMACEUTICALS, INC. | Health Technology |
| BRAINSTORM CELL THERAPEUTICS INC. | Health Technology |
| ELECTROCORE, INC. | Health Technology |
| Empresas privadas | 8 |
|---|---|
Pequot Capital Management, Inc.
 Pequot Capital Management, Inc. Investment ManagersFinance Founded in 1998 by Arthur J. Samberg, Pequot Capital Management Inc. is a hedge fund manager headquartered in Wilton, Connecticut with offices in New York City and Los Angeles. They manage the Pequot Family of Funds. | Finance |
| Sands Point Partners LP | |
JPMorgan Services (Malaysia) Sdn. Bhd.
 JPMorgan Services (Malaysia) Sdn. Bhd. Financial ConglomeratesFinance Part of JPMorgan Chase & Co., JPMorgan Services (Malaysia) Sdn. Bhd. operates a Malaysian investment company. Steve Clayton has been the CEO of the private company since 2011. | Finance |
EnzymeRx LLC
EnzymeRx LLC BiotechnologyHealth Technology EnzymeRx LLC develops pegylated uricase for the treatment of resistant and refractory related indications. The company was founded by Anthony S Fiorino in 2008 and is headquartered in Paramus, NJ. | Health Technology |
Immune Pharmaceuticals, Inc.
 Immune Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Its lead product, Bertilimumab, is a human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. It is also developing NanoCyclo, a topical nano-encapsulated formulation of cyclosporine, for the treatment of atopic dermatitis (AD) and psoriasis. The company was founded by Daniel Gedeon Teper on March 9, 1993 and is headquartered in Englewood Cliffs, NJ. | Health Technology |
Greywall Asset Management LP
Greywall Asset Management LP Investment ManagersFinance Greywall Asset Management LP is a hedge fund manager located in New York City. | Finance |
Triumvira Immunologics, Inc.
Triumvira Immunologics, Inc. Pharmaceuticals: MajorHealth Technology Triumvira Immunologics, Inc. develops and manufactures pharmaceutical products. The company was founded by Jonathan Bramson in 2015 and is headquartered in Hamilton, Canada. | Health Technology |
Alchimia Partners LLC
 Alchimia Partners LLC Miscellaneous Commercial ServicesCommercial Services Alchimia Partners LLC provides business support services. The private company is based in Teaneck. | Commercial Services |
- Bolsa de valores
- Insiders
- Tony Fiorino
